Price
No data yet.
Social Signal Score
Analyst Ratings
23 analystsRevenue
$3.55B-4.73%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Javier J. Rodriguez
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Employees
- 78,000
- Beta
- 0.83
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 1.68
Financials
Revenue
$3.55B-4.7%Net Income
$265.40M-53.5%EBITDA
$753.07M-24.9%Free Cash Flow
$320.25M+0.4%EPS (diluted)
$4.02+45.7%Shares Outstanding (diluted)
66.09M-68.1%Operating Expenses
$423.46MCash & Debt
$688.88MReturn of Capital
$514.31MRevenue by Segment (annual)
$11.73BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $13.64B | $746.80M | $9.72 |
| 2024 | $12.82B | $936.34M | $11.02 |
| 2023 | $12.14B | $691.53M | $7.62 |
| 2022 | $11.61B | $560.40M | $5.88 |
| 2021 | $11.62B | $978.45M | $9.30 |
| 2020 | $11.55B | $773.64M | $6.54 |
| 2019 | $11.39B | $810.98M | $5.29 |
| 2018 | $11.40B | $159.39M | $4.63 |
| 2017 | $10.88B | $663.62M | $3.52 |
| 2016 | $14.75B | $879.87M | $4.36 |
| 2015 | $13.78B | $269.73M | $1.27 |
| 2014 | $12.80B | $723.11M | $3.41 |
| 2013 | $11.76B | $633.45M | $3.02 |
| 2012 | $8.19B | $536.02M | $2.79 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from DVA's reported EPS growth of 10.1% a year over 13 years.
- EPS in 5 years
- $14.03
- Implied price
- $168.39
- Return from $178.72
- -1.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $83.72 — -53.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 8 | 10 | 12 | 14 | 16 |
|---|---|---|---|---|---|
| 0.1% | -17.2% | -13.4% | -10.2% | -7.3% | -4.8% |
| 5.1% | -13.0% | -9.0% | -5.7% | -2.7% | -0.1% |
| 10.1% | -8.9% | -4.7% | -1.2% | 1.9% | 4.7% |
| 15.1% | -4.7% | -0.4% | 3.3% | 6.5% | 9.4% |
| 20.1% | -0.6% | 3.9% | 7.8% | 11.2% | 14.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
30-60.00%Social Signal Score
Mentions (14)
- Newszacks.com·3d ago·Negative
DaVita HealthCare (DVA) Laps the Stock Market: Here's Why In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $178.69, denoting a +1.33% move from the preceding trading day.
View source ↗ - Newszacks.com·11d ago·Neutral
DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note The latest trading day saw DaVita HealthCare (DVA) settling at $174.67, representing a -4.62% change from its previous close.
View source ↗ - News (RSS)investing·19d ago·Positive
DaVita jumps 10% as AI strategy’s healthcare pick rides stronger guidance
View source ↗ - Newszacks.com·19d ago·Neutral
DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors DaVita HealthCare (DVA) closed the most recent trading day at $193.86, moving +1.55% from the previous trading session.
View source ↗ - Newsgurufocus.com·21d ago·Positive
A Look at DaVita Inc (DVA) After 4.3% Gain -- GF Value $195.67 vs Price $189.32 On September 14, 2026, DaVita Inc (DVA) shares rose 4.3% to $189.32, reflecting strong momentum as the stock trades within a 52-week range of $101.00 to $247.49
View source ↗ - Newszacks.com·26d ago·Positive
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now DVA gains from expanding value-based kidney care, improving dialysis volumes and clinical innovation, though payer-mix and regulatory risks persist.
View source ↗ - News (RSS)seekingalpha·30d ago·Neutral
Healthcare August recap: Moderna jumps 156% as biotech shines; DaVita sinks
View source ↗ - Newszacks.com·33d ago·Neutral
Do Options Traders Know Something About DaVita Stock We Don't? Investors need to pay close attention to DVA stock based on the movements in the options market lately.
View source ↗ - Newszacks.com·40d ago·Neutral
DVA & Humana Expand Value-Based Care for Kidney Disease Patients DaVita expands its Humana partnership to earlier-stage kidney disease, bringing value-based care to over 10,000 Medicare Advantage members.
View source ↗ - Newsprnewswire.com·41d ago·Neutral
Alebund Pharmaceuticals Announces 2026 Interim Results SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinic
View source ↗ - Newsprnewswire.com·42d ago·Neutral
DaVita Announces New Value-Based Partnership with Humana to Expand Care for Patients with Chronic Kidney Disease More than 10,000 members will get added support aimed at delaying or preventing dialysis and reducing hospitalizations DENVER, Aug. 25, 2026 /PRNewswire/ -- DaVita today announced a new value-based care agreement to deliver comprehensive, coordinated care to Humana Medicare Advantage members with chronic kidney disease (CKD) stages 3B–5. Launched July 1, this partnership builds on the…
View source ↗ - News (RSS)fortune·50d ago·Neutral
Berkshire Hathaway buys more homebuilder stocks but slashes stakes in banks and dumps all its holdings in alcoholic beverage maker Berkshire also reduced stakes in supermarket operator Kroger, steel manufacturer Nucor and dialysis giant DaVita.
View source ↗ - News (RSS)zerohedge·52d ago·Positive
…4.3MM shares added, or $118MMM, to $173.0MM Cuts: Bank of America (BAC), 30.2MM shares sold bringing total down to 483.4MM shares worth $27.5BN as of June 30 DaVita (DVA), 1.2MM shares sold bringing total to 28.9MM shares worth $6.4BN Kroger (KR), 11MM shares sold bringing total to 39MM shares worth $2.2BN Ally Financial (ALLY), 2MM shares sold bringing total to 27MM shares worth $1.2BN Capital One (COF), 4.2MM shares sold bringing total to 3MM shares worth $602MM Nucor (NUE), 2MM shares sold br…
View source ↗ - News (RSS)yahoo·55d ago·Positive
Are Wall Street Analysts Bullish on DaVita Stock?
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $3.55 per share
Typical surprise +4.7% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$4.02 vs $3.88beat
- Tue, May 5$2.87 vs $2.41beat
- Mon, Feb 2$3.40 vs $3.24beat
- Wed, Oct 29$2.51 vs $3.17miss
- Tue, Aug 5$2.95 vs $2.70beat
- Mon, May 12$2.00 vs $1.95beat
Estimates and results for DVA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DVA officers and directors.
- Bought
- —
- Sold
- $508.7m
0 trades
13 trades
- Berkshire Hathaway Incsold
- Rodriguez Javiersold
- Waters Kathleen Alycesold
- Waters Kathleen Alycesold
- Rodriguez Javiersold
- Hearty James Osold
- Maughan David Paulsold
- Maughan David Paulsold
87 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Julie Johnsonhouse · TX32 · disclosed Aug 6, 2026 (317d later)Sell$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Aug 6, 2026 (317d later)Buy$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Oct 8, 2025 (13d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (28d later)Sell$1,001 - $15,000
- Jerry Moransenate · KS · disclosed Jan 17, 2024 (34d later)Sell$1,001 - $15,000
- Jerry Moransenate · KS · disclosed Jan 17, 2024 (34d later)Sell$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Jan 12, 2024 (31d later)Sell$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Jul 14, 2023 (32d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jul 11, 2023 (12d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 12, 2023 (24d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Apr 7, 2023 (14d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 8, 2023 (22d later)Buy$1,001 - $15,000
- Jerry Moransenate · KS · disclosed Jan 21, 2022 (31d later)Sell$1,001 - $15,000
- Dean Phillipshouse · MN03 · disclosed Jun 13, 2019 (31d later)Sell$1,001 - $15,000
- Jerry Moransenate · KS · disclosed May 15, 2019 (160d later)Buy$1,001 - $15,000
- Jerry Moransenate · KS · disclosed May 15, 2019 (160d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA39 · disclosed Apr 16, 2019 (33d later)Sell$1,001 - $15,000
- Dean Phillipshouse · MN03 · disclosed Mar 21, 2019 (45d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.